Ikarian Capital’s Verona Pharma VRNA Stock Holding History

Ikarian Capital’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$5.23M	–	132
2022 Q4	$5.23M	Buy	+200,000	New	+$2.66M	1.26%	27

Other funds holding VRNA

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ikarian Capital's VRNA Position: Q3 2025 in Review

Ikarian Capital sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 146,831 shares — an estimated $13.9M sold.

Ikarian Capital first reported a position in VRNA in Q2 2022 and held it in 12 quarters. The position peaked at $13.9M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

Ikarian Capital reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
Ikarian Capital sold 146,831 Verona Pharma shares in Q3 2025, an estimated $13.9M.
Ikarian Capital first reported a position in Verona Pharma in Q2 2022 and held it in 12 quarters.
Ikarian Capital's Verona Pharma position peaked at $13.9M in Q2 2025.
243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.